抗体

Anti-CBL Antibody Picoband™

PB9077

100μg/vial

315美元

多克隆

domestic rabbit

未共轭

免疫印迹, 免疫细胞化学, 流式细胞仪, 免疫组化-石蜡切片

Anti-CBL Antibody Picoband™

315美元

100μg/vial

多克隆

兔

人类, 小鼠, 大鼠

流式细胞仪, IF, 免疫组化-P, 免疫细胞化学, 免疫印迹

Western blot, 0.1-0.5µg/ml, Human, Mouse, Rat. Immunohistochemistry (Paraffin-embedded Section), 0.5-1µg/ml, Human, Mouse, Rat, By Heat. Immunocytochemistry/Immunofluorescence, 2µg/ml, Human. Flow Cytometry, 1-3μg/1x10^6 cells, Human

WB: The detection limit for CBL is approximately 0.25ng/lane under reducing conditions. Tested Species: In-house tested species with positive results. By Heat: Boiling the paraffin sections in 10mM citrate buffer, pH6.0, for 20mins is required for the staining of formalin/paraffin sections. Other applications have not been tested. Optimal dilutions should be determined by end users.

Boster Bio Anti-CBL Antibody Picoband™ catalog # PB9077. Tested in Flow Cytometry, IF, IHC-P, ICC, WB applications. This antibody reacts with Human, Mouse, Rat.

Adding 0.2 ml of distilled water will yield a concentration of 500 μg/ml.

CBL

P22681

E.coli-derived human CBL recombinant protein (Position: A556-T906). Human CBL shares 84% amino acid (aa) sequence identity with mouse CBL.

冻干

Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg NaN3.

免疫原亲和纯化

No cross reactivity with other proteins

Store at -20˚C for one year from date of receipt. After reconstitution, at 4˚C for one month. It can also be aliquotted and stored frozen at -20˚C for six months. Avoid repeated freeze-thaw cycles.

Add 0.2ml of distilled water will yield a concentration of 500ug/ml.

E3泛素蛋白连接酶 CBL

E3 ubiquitin-protein ligase CBL; 6.3.2.-; Casitas B-lineage lymphoma proto-oncogene; Proto-oncogene c-Cbl; RING finger protein 55; Signal transduction protein CBL; CBL; CBL2, RNF55;

E3泛素蛋白连接酶 CBL

99633分子量

Adapter protein that functions as a negative regulator of many signaling pathways that are triggered by activation of cell surface receptors. Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor tyrosine kinases, including KIT, FLT1, FGFR1, FGFR2, PDGFRA, PDGFRB, EGFR, CSF1R, EPHA8 and KDR and terminates signaling. Recognizes membrane-bound HCK, SRC and other kinases of the SRC family and mediates their ubiquitination and degradation. Participates in signal transduction in hematopoietic cells. Plays an important role in the regulation of osteoblast differentiation and apoptosis. Essential for osteoclastic bone resorption. The 'Tyr-731' phosphorylated form induces the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function. May be functionally coupled with the E2 ubiquitin-protein ligase UB2D3.

Cytoplasm. Cell membrane. Colocalizes with FGFR2 in lipid rafts at the cell membrane.

Boster recommends Enhanced Chemiluminescent Kit with anti-Rabbit IgG (EK1002) for Western blot, and HRP Conjugated anti-Rabbit IgG Super Vision Assay Kit (SV0002-1) for IHC(P) and ICC.

Contains 1 Cbl-PTB (Cbl-type phosphotyrosine-binding) domain.

CBL (Cbl proto-oncogene) is also known as C-CBL, RNF55, CBL2 and E3 ubiquitin protein ligase. CBL is mapped to chromosome 11q23.3-qter by molecular characterization of the breakpoints in 2 somatic cell hybrids. The encoded protein is one of the enzymes required for targeting substrates for degradation by the proteasome. This protein mediates the transfer of ubiquitin from ubiquitin conjugating enzymes (E2) to specific substrates. This protein also contains an N-terminal phosphotyrosine binding domain that allows it to interact with numerous tyrosine-phosphorylated substrates and target them for proteasome degradation. As such it functions as a negative regulator of many signal transduction pathways. This gene has been found to be mutated or translocated in many cancers including acute myeloid leukaemia. Mutations in this gene are also the cause of Noonan syndrome-like disorder.

Adapters, Cancer, Cancer Susceptibility, Cell Biology, Co-Activators/Co-Repressors, Cytoplasmic, Epigenetics and Nuclear Signaling, Nuclear Hormone Receptors, Nuclear Receptors, Nuclear Signaling, Nuclear Signaling Pathways, Oncoproteins, Oncoproteins/Suppressors, Proteasome / Ubiquitin, Proteolysis / Ubiquitin, Proto-Oncogenes, Ring Finger E3 Ligase, Signal Transduction, Signaling Pathway, Transcription, Ubiquitin E3 Enzymes